Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.78 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.78 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726535 | 0.99 | ABCC9 (0.77) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL726534 | 0.99 | ABCC9 (0.77) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6361002 | 0.94 | ABCC9 (0.70) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6363889 | 0.94 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL728039 | 0.93 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6364340 | 0.93 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6358933 | 0.93 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6363036 | 0.93 | ABCC9 (0.68) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6358867 | 0.93 | ABCC9 (0.68) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 | |
| SCHEMBL6358556 | 0.93 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11ALDH1A1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4733268-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| US-6414030-B1 | 1-((5-(2-(5-TERT-BUTYL-2-METHOXYBENZAMIDO)ETHYL)-2-METHOXYPHEN YL)-SULFONYL)-3-METHYLTHIOUREA AND PROPANOLOL FOR EXAMPLE | AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) | 2002-07-02 | — | — | US | claimed |
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | US | claimed |
| EP-1117409-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | Aventis Pharma Deutschland GmbH (DE) | 2001-07-25 | — | — | EP | claimed |
| WO-2000015204-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | claimed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-6414030-B1 | 1-((5-(2-(5-TERT-BUTYL-2-METHOXYBENZAMIDO)ETHYL)-2-METHOXYPHEN YL)-SULFONYL)-3-METHYLTHIOUREA AND PROPANOLOL FOR EXAMPLE | AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) | 2002-07-02 | — | — | US | disclosed |
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | US | disclosed |
| EP-1117409-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | Aventis Pharma Deutschland GmbH (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000015204-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | UTS2R, TST, SIGMAR1 | ABCC9 340/4885ABCC8 196/4885KCNJ11 252/4885 |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCC8 415/4885KCNJ11 18/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885ABCC8 605/4885KCNJ11 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.